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Abstract
 
Mutations within cytotoxic T lymphocyte (CTL) epitopes impair T cell recognition, but escape
mutations arising in flanking regions that alter antigen processing have not been defined in natural
human infections. In human histocompatibility leukocyte antigen (HLA)-B57
 
  
 
HIV-infected
persons, immune selection pressure leads to a mutation from alanine to proline at Gag residue
146 immediately preceding the NH
 
2 
 
terminus of a dominant HLA-B57–restricted epitope,
ISPRTLNAW. Although N-extended wild-type or mutant peptides remained well-recognized,
mutant virus–infected CD4 T cells failed to be recognized by the same CTL clones. The
A146P mutation prevented NH
 
2
 
-terminal trimming of the optimal epitope by the endoplasmic
reticulum aminopeptidase I. These results demonstrate that allele-associated sequence variation
within the flanking region of CTL epitopes can alter antigen processing. Identifying such
mutations is of major relevance in the construction of vaccine sequences.
Key words: CD8 T cell responses • viral evolution • immune evasion • antigen presentation 
 
Introduction
 
CTL activity plays an important role in the immune control
of chronic viral infections such as EBV, CMV, and HIV
(1–5). A variety of strategies have evolved by which these
viruses successfully evade elimination by the CTL response,
indicating the importance of these cells in viral contain-
ment (6). Viral escape via mutation within CTL epitopes
has been well documented in acute and chronic immuno-
deficiency virus infection (7–15). In all of these cases, the
mutation occurred within the epitope and it led either to a
reduction in binding to the MHC class I molecule and/or
to altered T cell receptor recognition.
Interference with intracellular antigen processing may
also lead to loss of recognition. This could arise at any stage
in the processing pathway, including the degradation of viral
proteins by cytosolic proteases, mainly the 26S proteasomes
(16, 17); the destruction of the proteasome products by
peptidases in the cytosol or the ER (18–20); the binding of
oligopeptides to the transporter associated with antigen
processing (TAP) and their translocation into the ER (21,
22); and the trimming of precursors into antigenic peptides
of the correct length to bind to the MHC class I molecule
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(19, 23, 24). The involvement of an ER-resident ami-
nopeptidase termed ER aminopeptidase I (ERAPI) in the
NH
 
2
 
-terminal trimming of N-extended antigenic peptides
for loading onto class I molecules was recently demon-
strated in the murine system (25–27).
Interference with antigen processing has been induced
by specific viral proteins, for example in CMV and HSV
infection (28), but theoretically could be achieved by vi-
ral sequence mutations. Several groups have shown that
the artificial mutation of the flanking sequence of CTL
epitopes can lead to loss of recognition (29–35). However,
thus far there is no in vivo evidence that immune selection
pressure leads to CTL escape by altered antigen processing,
even though such evidence has been sought (36). Here we
present evidence for allele-specific positive selection of es-
cape mutation within the flanking region of a defined CTL
epitope within the course of a natural human infection.
This mutation leads to the inability of ERAPI to cleave the
variant N-extended peptide to the optimal size.
 
Materials and Methods
 
Study Patients.
 
HIV-1 clade B– or clade C–infected individ-
uals of different disease status were recruited at the Cato Manor
Clinic, Durban, South Africa, Queen Elizabeth II Hospital,
Bridgetown, Barbados, Wycombe General Hospital, UK, the
Harrison Clinic, Radcliffe Infirmary, Oxford, UK, and the Mas-
sachusetts General Hospital, Boston, MA. HLA class I typing was
performed at Dynal Biotech, Oxford, UK. The study was ap-
proved by the institutional review boards at the University of
Natal, at Queen Elizabeth II Hospital, by the Oxford Research
Ethics Committee, and the Massachusetts General Hospital Insti-
tutional Review Board. All individuals gave informed consent for
participating in this study.
 
Sequencing.
 
Proviral DNA was extracted from fresh PBMCs
using the Puregene™ DNA isolation kit. HIV-Gag sequences
were amplified by nested PCR as previously described (37). Se-
quencing reactions were performed using the ABI Prism Big-
Dye™ Ready Reaction and using the six primers previously de-
scribed (37). The plates were analyzed on the ABI 3700 DNA
Analyzer from Applied Biosystems.
 
ELISPOT.
 
HIV-1–specific CD8 T cell responses were
quantified by ELISPOT assay using fresh or frozen PBMCs (0.5–
1 
 
  
 
10
 
5 
 
per well) and single peptides (final concentration of 20
 
 
 
g/ml) as previously described (38).
 
Cell Lines.
 
EBV-transformed B lymphoblastoid cell lines were
established in R20 medium (RPMI 1640; Sigma-Aldrich) supple-
mented with 2 mM 
 
l
 
-glutamine, 50 U/ml penicillin, 50 
 
 
 
g/ml
streptomycin, 10 mM Hepes, and 20% heat-inactivated FCS
(Sigma-Aldrich). CTL clones were isolated by limiting dilution and
characterized and maintained as previously described (39), using the
CD3-specific mAb 12F6 and irradiated feeder cells as stimulus for T
cell proliferation. For this study, we used CTL clones specific for
the following epitopes: B57 KAFSPEVIPMF, B57 ISPRTLNAW,
and A31 RLRDLLLIVTR. Specific lysis for all clones was 70–90%
in 
 
51
 
Cr release assay at the E/T ratio of 10:1. Primary CD4 cells
were derived from PBMCs of an HIV-uninfected donor with the
HLA class I genotype: HLA A2, 11; B57; Cw7, 11. CD4 T cells
were expanded using the bispecifc mAb CD3/CD8.
 
51
 
Cr Release Assay.
 
B lymphoblastoid cell line target cells
were labeled with 50 
 
 
 
Ci Na
 
2
 
(
 
51
 
CrO
 
4
 
) (1 Ci 
 
  
 
37 GBq; New
England Nuclear) for 1 h at 37
 
 
 
C, 5% CO
 
2
 
. Targets were incu-
bated with peptide either at the time of Cr labeling or after wash-
ing twice with peptide dilutions for titration assays. CTL clones
were added as effectors at the E/T ratio of 10:1 or 5:1. Superna-
tants were harvested after an additional 4-h incubation at 37
 
 
 
C,
5% CO
 
2
 
. For assays using primary CD4 cells as targets, primary
CD4 cells were infected with either WT or mutant virus at a
multiplicity of infection (MOI) of 1 and used on day 4 after in-
fection. Infection rates were comparable for both viruses: 8.6 and
8.7%, respectively, as measured by intracellular p24 staining.
 
Site-directed Mutagenesis.
 
The mutant virus A146P was con-
structed by substituting an alanine with a proline in position 146
of HIV-1 Gag with the GeneTailor™ Site-Directed Mutagenesis
System (Invitrogen). The whole plasmid DNA was PCR ampli-
fied in a mutagenesis reaction with two overlapping primers, one
of which contains the target mutation: p24/1209–1238 5
 
 
 
-GCA
AAT GGT ACA TCA GCC CAT ATC ACC TAG-3
 
  
 
and
p24/1222–1195 5
 
 
 
-GAT GTA CCA TTT GCC CCT GGA
GGT TCT G-3
 
 
 
. The presence of A146P was verified by DNA
sequencing from nucleotide position 983 to 1656 in Gag in
newly generated plasmid clones. Infectious virus was produced by
cotransfection of MT-4 cells with the mutant proviral 5
 
  
 
half-
genome plasmid and the HIV-1
 
NL4–3 
 
3
 
  
 
half-genome plasmid (p83-
10; references 40 and 41).
 
Growth Competition Assays.
 
Infections were initiated with
unequal amounts of two competing virus variants, typically 10
and 90%, based on virus infectivity titrations. Inocula of 5,000
TCID
 
50 
 
of each virus were used to infect 5 
 
  
 
10
 
6 
 
stimulated
PBMCs (MOI 
 
  
 
0.001) as previously described (42, 43). PBMCs
were also separately infected with the mutant A146P in the ab-
sence of WT virus to evaluate the potential for true genetic re-
version over the course of the experiment. 5-ml cultures were
maintained in six-well tissue culture plates at 0.5 
 
  
 
10
 
6 
 
cells/ml.
At day 3 of the first passage, half of the culture was replaced with
fresh medium. At day 7, fresh MT-4 cells were reinfected with a
dilution of 1:10 of the supernatant and cultured at 0.5 
 
  
 
10
 
6
 
cells/ml. Two additional passages were performed in the same
way. Cell-free supernatant fluid aliquots were taken at the end of
the culture and viral RNA was extracted (QIAamp™ Viral RNA
kit; QIAGEN). The relative proportion of the two competing
variants was determined over time based on the relative peak
heights in electropherograms obtained by automated sequencing
of HIV-1 p24 from culture supernatants. To further quantify the
proportion of sequences expressing the A146P (GCC to CCC)
mutation, allele-specific real-time PCR combining nonselective
and selective primer pairs was also used. For nonselective am-
plification, we used primer sets ISW9-Fw (1144–1165) 5
 
 
 
-
GCAGCTGACACAGGAAACAA-CA-3
 
  
 
and ISW9NS-Rv
(1227–1254) 5
 
 
 
-CCATGCATTTAAAGTTCTAGGTGAT-
ATG-3
 
  
 
and the TaqMan MGB probe ISW9_Pr (1167–1181)
5
 
 
 
-(6-FAM)CCAGGTCAGCCAAAA-3
 
  
 
obtained from Applied
Biosystems. For preferential amplification of Ala-146, the
ISW9NS-Rv primer was replaced by the primer ISW9Swt-Rv
(1225–1250) 5
 
 
 
-GCATTTAAAGTTCTAGGTGATATCGC-
3
 
 
 
. This primer included an intentional mismatch at the 
 
 
 
2 posi-
tion relative to the 3
 
  
 
terminus of the oligonucleotide with the
objective to destabilize the amplification of mutant sequences.
Samples were evaluated by real-time PCR using an ABI PRISM
7000 sequence detection system (Applied Biosystems) with the
following cycling parameters: 50
 
 
 
C for 2 min, 95
 
 
 
C for 10 min,
followed by 40 cycles at 95
 
 
 
C for 15 s and 60
 
 
 
C for 1 min. The
number of cycles required to reach threshold fluorescence (
 
Ct
 
)
was determined, and the quantity of sequences initially present 
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was calculated by extrapolation onto the standard curve. The
same dilutions of standard (plasmid containing the Ala-146) were
used for both the nonselective and the Ala-146–selective amplifi-
cations. The percentage of viral sequences containing Ala-146
was then calculated as follows: % Ala-146 sequences 
 
  
 
[(quantity
of Ala-146 sequences in the sample)/(quantity of total sequences
in the sample)] 
 
  
 
100. Nonselective and selective amplifications
were always performed at the same time. All reactions were per-
formed in triplicate and the mean of the three values was used for
calculations.
 
Viral Replication Inhibition Assay.
 
Inocula of 80,000 TCID
 
50
 
of either HIV-1 NL4-3 WT or A146P mutant virus were used to
infect 8 
 
  
 
10
 
6 
 
primary CD4 cells (MOI 
 
  
 
0.01) on day 7 after
stimulation with the bispecific antibody CD3/CD8. These were
cultured with HIV-1–specific CTL clones at E/T ratios 4:1, 1:1,
and 1:4 in duplicate in 24-well plates in 2 ml. All assays were per-
formed in R10 with 50 U/ml rIL-2. Half of the supernatant was
harvested for quantitative HIV-1 p24 antigen capture ELISA
(Dupont) and replenished with fresh medium at the indicated
time points after infection (44).
 
ERAPI Assay.
 
The peptides used were 
 
 
 
90% pure by mass
spectrometry analysis. 50 nmol/ml of NH2-extended peptides
were incubated at 37
 
 
 
C with 3.5 
 
 
 
g/ml human recombinant
ERAPI in a buffer containing 50 mM Tris-HCl, pH 7.8. At each
time point a 50-
 
 
 
l aliquot was removed and the reaction was
stopped by adding an equal volume of 0.6% trifluoroacetic acid.
Samples were loaded on a 4.6 
 
  
 
50-mm TARGA 3-
 
 
 
m C18
column (Higgins Analytical, Inc.) in 10 mM sodium phosphate
buffer, pH 6.6, containing 7% acetonitrile. Elution was per-
formed with a linear 7–31.5% acetonitrile gradient. The amount
of a trimmed peptide was calculated by the integration of peptide
peaks. The identity of peaks was determined by comparing their
retention time to those of pure synthetic peptides.
 
Phylogenetic Analysis of Selection Pressures.
 
We used a maxi-
mum likelihood method that assesses the fit to the data of various
models of codon evolution that differ in how 
 
d
 
N
 
/
 
d
 
S 
 
varies across
the sequence alignment and takes into account the phylogenetic
relationships of the sequences in question (45). We used two
models of codon evolution: “M7,” which specifies ten categories
of 
 
d
 
N
 
/
 
d
 
S 
 
in the alignment, none of which may be 
 
 
 
1 so that evo-
lution is entirely neutral, and “M8,” which only differs from M7
in that it incorporates an extra (11th) class of codons that can take
on any value of 
 
d
 
N
 
/
 
d
 
S
 
, including those supporting positive selec-
tion (
 
d
 
N
 
/
 
d
 
S 
 
  
 
1). The selection pressures at individual codons can
then be assessed using Bayesian methods. All analyses were un-
dertaken using the CODEML program from the PAML package
(46) with input phylogenetic trees inferred using the maximum
likelihood method available in the PAUP
 
* 
 
package (47).
 
Online Supplemental Material.
 
The Online Supplemental Ma-
terial shows the sequence data of HIV transmission pairs (Table
S1), the phylogenetic tree showing the relationship of the viruses
of the transmission pairs (Fig. S1), the HPLC elution times for
synthetic peptides used in this study (Table S2), and comparison
of viral replication fitness of A146 wild-type and A146P mutant
virus (Fig. S2). Supplemental Materials and Methods, Tables S1
and S2, and Figs. S1 and S2 are available at http://www.jem.org/
cgi/content/full/jem.20031982/DC1.
 
Results
Identification of Allele-specific Mutations in Persons Express-
ing HLA-B57. Complete Gag sequencing in 174 clade
C–infected persons revealed two sites at which there were
differences in consensus sequence between persons express-
ing HLA-B57 and those not expressing this allele. Both sites
were within regions encoding defined HLA-B57–restricted
epitopes: ISPRTLNAW (“ISW9,” HXB2 Gag residues
147–155; Fig. 1 A) and TSTLQEQIAW (“TW10,” residues
240–249; reference 37). For TW10, the amino acid change
Figure 1. Amino acid sequences of the region spanning
the ISPRTLNAW epitope (Gag residues 142–160).
Consensus sequence as listed in the Los Alamos Database
(top row), consensus sequence according to the sequence
data obtained from B57  subjects (middle row), and
non-B57  subjects (bottom row) for clade C (A) and
clade B (B). Listed below are the actual sequence data
for 174 clade C–infected subjects and 100 clade
B–infected subjects. For clade C–infected subjects, varia-
tion at residues 146 and 147 was associated with ex-
pression of B57 (P   0.0001 and P   0.0001, respec-
tively, Fisher’s exact test), as well as in clade B–infected
subjects (P   0.03 and P   0.0006, respectively).Escape Mutation Resulting in Antigen Processing Failure 908
was situated within the previously described epitope located
at position 3, believed to be a TCR contact residue (48). Of
the two amino acid changes in relation to the ISW9 epitope
that were specific to HLA-B57  subjects, one was found
at Gag residue 147 located at the NH2-terminal position
within epitope (49). The other was an alanine to proline
change at Gag residue 146 immediately preceding the NH2-
terminal amino acid position (Fig. 1 A). The same analysis
was performed in 100 persons infected with HIV clade B,
and similar significant differences in sequences were ob-
served in HLA-B57  persons (Fig. 1 B).
Analysis of the specific polymorphisms at residues 146 and
147 revealed strong allele-specific selection for certain amino
acids. When the clade B and clade C cohorts were com-
bined and analyzed, 37 out of 61 (61%) of B57  subjects had
variation at residue 146 involving an A146P polymorphism
versus 30 out of 213 (14%) of non-B57 controls (relative
risk   4.3; P   0.0001). Similarly, the variation at position
Gag 147 involved an isoleucine to leucine polymorphism
(“I147L”) in 43 out of 61 (70%) of B57  subjects versus 44
out of 213 (21%) of non-B57 controls (relative risk   3.4;
P   0.0001). The association of these A146P and I147L
mutations with HLA-B57 expression was less strong in B
clade infection than in C clade infection, although remain-
ing significant (P   0.03 and 0.0006, respectively).
HLA-B57–specific Positive Selection Pressure Drives Varia-
tion at Position 146 and Is Found after Transmission in Persons
Expressing HLA-B57. To determine whether the varia-
tion observed at residues 146 and 147 was the result of pos-
itive selection pressure, the ratio of nonsynonymous to syn-
onymous nucleotide change (dN/dS) was calculated for each
individual codon in Gag and analyzed using the maximum
likelihood of Yang (45). Initial studies were performed in
clade C–infected persons, where the association between
polymorphism in Gag and expression of HLA-B57 was
strongest. Amino acid variation was observed at only two
sites within Gag that was under positive selection (dN/dS  
1) specific to B57  subjects (not depicted). These were at
Gag residue 242 (within the TW10 epitope) and at Gag
residue 146, immediately preceding the ISW9 epitope
(mean dN/dS: 3.22). There was no evidence of positive se-
lection at these sites when sequences from HLA-B57  sub-
jects alone were analyzed, nor was there evidence of posi-
tive selection for the conservative I147L mutation.
To further demonstrate that the variation at Gag residues
146 and 147 involves immune selection pressure mediated
by HLA-B57, we sought examples of known transmission
of virus from an individual expressing neither of these al-
leles to an HLA-B57  individual. Three such mother-child
pairs and a pair of hemophiliacs were identified, in which
the WT virus was present in the HLA-B57  mother/do-
nor. The A146P and/or I147L variants arose subsequent
to transmission in each B57  child/recipient (Table S1,
available at http://www.jem.org/cgi/content/full/jem.
20031982/DC1). In each of the pairs evaluated, the com-
mon ancestry of the viruses was confirmed by phylogenetic
analysis (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20031982/DC1).
The A146P Mutation Is in the Epitope’s Flanking Region
and Is Associated with Low Frequency ISW9-specific CTL Ac-
tivity and High HIV Viral Load. The finding of an HLA-
B57–specific difference in the consensus sequence at Gag
residue 146 was unexpected as it did not lie within the de-
fined CTL epitope. Because previous studies have shown
that HLA-B57 can accommodate peptides of different lengths
and that one HLA-B57 epitope can lie entirely within an-
other (50), we examined the possibility that residue 146
might indeed lie within a targeted epitope. Data from
the  study of seven HLA-B57  individuals showed that
ISPRTLNAW (ISW9) is the only HLA-B57–restricted
epitope in this region (not depicted) and confirmed that it
is the best-recognized epitope at low peptide concentra-
Figure 2. Impact of A146P mutation using
synthetic peptides. (A and B) Peptide titration
ELISPOT using ISW9 and WT or mutant
N-extended synthetic peptides. Results are rep-
resentative for assays using ex vivo PBMCs of
seven different individuals recognizing ISW9.
(C) Ex vivo ELISPOT response toward ISW9
in 38 subjects according to the sequence of the
autologous virus at residue Gag 146. P   0.09,
Mann-Whitney test. Magnitude of ISW9 re-
sponse for subjects with A146, median 560
(range 0–4,120) spot-forming cells/million
PBMCs; for subjects with A146P, median 100
(range 0–500) spot-forming cells/million PBMCs.
(D) Association of A146P expression with
higher viremia. All HAART-naive HLA-B57 
subjects from these cohorts and those for
whom published data are available (reference
41) were included for analysis. P    0.006,
Mann-Whitney test.Draenert et al. 909
tions (Fig. 2 A). There was no difference in recognition of
N-extended WT or A146P-mutant synthetic peptides
when using PBMCs in an ex vivo ELISPOT assay (Fig. 2
B). In addition, ISW9-specific CTL clones recognize both
the WT and mutant peptides using peptide-pulsed HLA-
B57  primary CD4 T cells as targets (not depicted). How-
ever, in spite of the preserved recognition of mutant pep-
tides, a trend toward stronger responses was seen in
persons expressing alanine at position 146 (P    0.09;
Mann-Whitney test), and for those with a positive re-
sponse, the magnitude was significantly greater in persons
with the A146 WT autologous sequence (P    0.02;
Mann-Whitney test; Fig. 2 C).
To address the question of whether this A146P flanking
mutation might be associated with less effective control of
HIV infection in HLA-B57  subjects, we compared viral
load in B57  subjects whose autologous virus encoded the
A146P mutant with that in B57  subjects whose autologous
virus encoded the A146 WT. Despite the considerable di-
versity in our own and in the other B57  cohorts (51) for
which these data are available, this single amino acid change
is associated with a 22-fold increase in viral load (median:
483 HIV RNA copies/ml vs. 10,521 HIV RNA copies/ml;
P   0.006; Fig. 2 D). This compares with a 5.1-fold differ-
ence between the 75th and 25th centiles for viral load in the
MACS cohort (52). Because viral load is a strong predictor
of disease progression (53), this A146P mutation is associated
with a substantially increased risk of disease progression.
These results confirm that although the A146P mutation
is associated with HLA-B57 and is the result of HLA-B57–
associated positive selection, it does not lie within the re-
gion targeted by the TCR but instead in the flanking re-
gion of the ISW9 epitope, thus providing evidence for an
escape mechanism involving antigen processing. In those
subjects targeting the ISW9 epitope, the magnitude of the
response is lower in association with the A146P mutation.
Furthermore, this A146P mutation appears to have signifi-
cance for HLA-B57  subjects because this mutation is asso-
ciated with high viremia and therefore higher risk of pro-
gression to disease.
The A146P Mutation Leads to Impaired Recognition of Vi-
rus-infected Cells by ISW9-specific CTL Clones. Because the
use of synthetic peptides to pulse target cells does not in-
volve intracytoplasmic generation of peptides and therefore
does not assess potential alterations in antigen processing that
might be induced by the flanking residue mutation, we next
constructed viruses differing only at position Gag 146, the
NL4-3 WT virus and a mutant virus isogenic with NL4-3
except in expression of proline at Gag residue 146. Cytotox-
icity assays using CTL clones as effectors and virus-infected
primary CD4 T cells from an uninfected HLA-B57  donor
as targets showed that WT infected target cells were lysed
by ISW9-specific clones but mutant infected cells were
not (Fig. 3 A). In contrast, HLA-B57–restricted KAFSPE-
VIPMF (“KF11”)-specific CTL (targeting a p24 Gag epi-
tope conserved in both viruses) lysed cells infected with
either virus, and, as expected, an HLA-mismatched HLA-
A31–restricted CTL clone did not lyse either of the target
cells. The proportion of targets infected with WT and mu-
tant virus as assessed using intracellular cytokine staining of
targets by anti-p24 antibody was identical (9% in each case).
Viral replication inhibition assays using the same effec-
tors and targets further confirmed preferential targeting of
the WT virus over the A146P mutant, whereas control
CTL specific for an epitope conserved in both viruses in-
hibited both viruses and the HLA-mismatched clone did
not inhibit either virus (Fig. 3 B). These data suggest that
the A146P mutation acts as a processing mutant by which
the virus can evade the ISW9-specific response.
The A146P Mutation Results in Altered Trimming by
ERAPI. Next, we evaluated the effects of the A146P
mutation on epitope processing. ERAPI is the first ER-res-
ident aminopeptidase shown to be involved in antigen pre-
sentation (25–27). Reported studies were undertaken in
the mouse model and although it is likely that they ap-
ply also to the human system, direct evidence for the in-
Figure 3. Impact of the A146P mutations using single
point mutation viruses. (A) 51Cr release assay using CTL
clones as effectors (E/T ratio, 100:1) and primary CD4 T
cells as targets infected either with A146 WT virus or
A146P mutant virus (MOI   1). Infection rates were 8.6%
for A146 WT virus and 8.7% for A146P mutant virus.
Representative results for three assays using ISW9 clones of
two different donors. (B) Replication inhibition assay
using A146 WT or A146P mutant–infected primary CD4
cells (MOI   0.01) and CTL clones as effectors. Represen-
tative results for five assays and ISW9 clones of two differ-
ent subjects. ISW9, ISPRTLNAW; KF11, KAFSPEVIPMF;
RR11, RLRDLLLIVTR.Escape Mutation Resulting in Antigen Processing Failure 910
volvement of ERAPI in the trimming of HLA-restricted
N-extended epitopes has not yet been presented. Like
other aminopeptidases, ERAPI cannot hydrolyze an X-P
bond (23, 25) and we therefore investigated whether
ERAPI might be involved in the NH2-terminal trim-
ming of the N-extended ISW9 epitope. We focused our
study on four N-extended WT or mutant ISW9 peptides
(MVHQA/P-ISW9, HQA/P-ISW9, QA/P-ISW9, and
A/P-ISW9). These 9–14 mers fall into the range of peptide
lengths translocated by TAP into the ER (54).
The unique HPLC profiles and elution times were de-
termined for each synthetic peptide to serve as standards
(Table S2, available at http://www.jem.org/cgi/content/
full/jem.20031982/DC1). We then incubated ERAPI
with the WT and variant peptides for 0, 1, 2, and 4 h and
performed reverse phase HPLC profile analysis of the di-
gestion products (Fig. 4 A). In 1 h the HQA-ISW9 peptide
is trimmed to a mix of QA-ISW9 and A-ISW9, showing
that this N-extended HLA-B57–restricted epitope is a sub-
strate for ERAPI, and by 4 h the major product is the opti-
mal ISW9 peptide (Fig. 4 A). In contrast, HQP-ISW9 is
trimmed to QP-ISW9 in 2 h and no other products are
produced even at 4 h.
Next, we studied the digestion products obtained after
incubation of each intermediate peptide as well as ISW9
and SW8 (Fig. 4 B). All WT N-extended peptides are
trimmed to a mix of  50% ISW9 and 50% SW8 (except
QA-ISW9, for which SW8 represents 75% of the final
product), whereas the mutants are never fully trimmed to
the optimal epitope. These results demonstrate that if these
10–14-mer peptides indeed reach the ER lumen, ERAPI
is able to process only those peptides containing an ala-
nine at residue 146, but cannot trim any of the 10–14-mer
N-extended ISW9 peptides containing a proline at position
146 down to the optimal epitope. Thus, these results are
consistent with the lack of CD8 T cell recognition of cells
infected with HIV containing proline at Gag residue 146.
Accumulation of A146P Variants over Time in the Population.
To determine whether the A146P mutation affected viral
fitness, replication of the WT NL4-3 virus was compared
in culture to that of the A146P mutant virus that had
been generated. Both in these experiments (Fig. 3 B) and
in competition experiments in which relative replication
fitness was analyzed (Fig. S2, available at http://www.
jem.org/cgi/content/full/jem.20031982/DC1), there was
no evidence that viral fitness was compromised by the
A146P mutation. It was therefore hypothesized that trans-
mission of this variant to an individual lacking HLA-B57
would not result in its disappearance, and that persistence
of this variant would be reflected in an accumulation of this
variant over time through the epidemic. Sequences in the
Los Alamos database with a known sampling date show
that of the B clade sequences obtained from subjects early
in the epidemic, for example pre-1995, only 2 out of 48
(4%) showed variation at Gag residue 146, compared with
29–31% of sequences obtained from subjects sampled later
in the epidemic (between 1995 and 1999 or since 2000 us-
ing the clade B–infected samples used in Fig. 1; P  
0.0001; Fig. 5 A). Out of 19 acutely infected subjects in
Boston (B clade) whose virus was sampled before serocon-
Figure 4. Trimming of N-extended WT and mutant
ISW9 by ERAPI. (A) HQA-ISW9 or HQP-ISW9
were incubated with human recombinant ERAPI. At
each time point an aliquot was removed and fraction-
ated by reverse phase HPLC. 100% correspond to 50
nmol/ml. (B) Hydrolysis rates and digestion products
obtained after a 4-h incubation of each intermediate
A146 or A146P peptide with ERAPI.Draenert et al. 911
version (1997–2001; reference 55), 47% showed virus-
encoding mutants at A146 (P   0.0001). Transmission of
virus from an HLA-B57  mother to an HLA-B57  child
showed that over 8 yr there was no reversion in this A146P
mutation (Fig. 5 B), in contrast to a mutation in the B57-
restricted TW10 epitope (37). The percentage of mutations
at position Gag 146 is lower in the B57  clade C–infected
individuals than in the B57  clade B–infected cohort (13
vs. 29%) sequenced for this study. These C clade–infected
subjects were recruited in South Africa where the HIV ep-
idemic is much younger, which may explain why the accu-
mulation is not visible to date. One may therefore hypoth-
esize that this process of transmission of the A146P mutant
and maintenance in the absence of the evolutionary force
that originally drove its selection would gradually lead to
the loss of ISW9 as an HLA-B57–restricted epitope as the
epidemic progresses.
Discussion
Here we present evidence of immune escape due to viral
mutation in the flanking region of an epitope that is in-
duced by CTL selection pressure. Variant peptide-pulsed
target cells were well recognized but variant virus-infected
cells were not well seen either in cytotoxicity assays or in
viral inhibition assays in vitro. The processing variant,
occurring in the NH2-terminal flanking position of the
epitope, involved a substitution of proline for alanine and,
if the N-extended peptide were to reach the ER lumen,
this substitution would lead to the inability of ERAPI to
cleave the peptide to the optimal size. This is the first study
to address the role of ERAPI in trimming of the NH2 ter-
minally extended peptide in the human system. The func-
tional importance of this processing mutation is evidenced
by the demonstration that it arises as a consequence of pos-
itive selection pressure in association with HLA-B57 ex-
pression. Subjects who targeted the ISW9 epitope and in
whom the A146P mutation was present showed weaker
recognition of the ISW9 peptide affected by the processing
mutation. Furthermore, the A146P mutation was associ-
ated with a 22-fold higher viral load in HAART-naive
subjects with B57. Finally, viral replication capacity was
not reduced by this A146P mutation in vitro, consistent
with evidence presented that this mutation is accumulating
in the viral population over time.
Although proposed for many years, evidence that intra-
host mutations in the flanking region of a CTL epitope can
lead to immune escape in a natural human viral infection
has been absent. It has been shown that either inserting a
CTL epitope at different positions into unrelated carrier
Figure 5. Accumulation of the A146P muta-
tion in the population. (A) Percentage of se-
quences with amino acid variation at Gag residue
146 by date of sampling in clade B–infected
individuals. Sequences from subjects with a
known sampling date were taken from the Los
Alamos HIV Sequence Database (http://hiv-web.
lanl.gov) and included 100 B clade sequences for
the 2000–2003 time period from the subjects
whose virus was sequenced for this paper, of
whom 70 were HLA-B57  (see Fig. 1 B). The
acute preseroconversion group was recruited at
the Massachusetts General Hospital as part of
the “acute infection cohort” (reference 55).
Statistical analysis was performed using the
Fisher’s exact test. (B) Population sequencing
and sequencing of multiple clones in an HLA-
B57  mother who transmitted the virus to a
HLA-B57  child at different time points.Escape Mutation Resulting in Antigen Processing Failure 912
proteins or mutating the flanking region of an epitope can
affect epitope presentation (29, 31–34). A natural mutation
in the C terminus of a murine leukemia virus CTL epitope
led to the abolition of proper epitope presentation (35).
Yellen-Shaw et al. (30), using a mouse model of influenza
infection, experimentally substituted proline for alanine
immediately upstream of the H-2Kd influenza NP147–155
epitope, and demonstrated that the mutation blocks pre-
sentation of this epitope. The data presented here indicate
that a similar alanine to proline substitution can occur as a
consequence of natural selection pressure, and thus pro-
vides evidence of a mechanism for immune escape in
chronic human viral infections.
It is unclear why the adjacent intra-epitopic mutation
I147L is associated with HLA-B57 expression and yet phy-
logenetic analysis failed to demonstrate positive selection at
this site. Two possibilities seem likely. First, that amino
acid changes at site 147 occurred less often and at deeper
branches of the tree than those at site 146, so that there was
insufficient variability to detect positive selection under the
analytical methods used here. Alternatively, it might be that
the I147L mutation in HLA-B57  patients is not selected
in itself, but rather is in linkage with the selected mutation
at site 146. To resolve these theories will evidently require
the analysis of this epitope in a larger sample of patients.
The processing mutant we characterized may result from
a failure of ERAPI to trim NH2-terminal residues flanking
the optimal peptide. In common with other aminopepti-
dases, ERAPI fails to cleave the NH2-terminal residue
when it is followed by a proline (X-P-epitope), at least in
the case of an artificial mutation introduced upstream from
a mouse epitope (23, 25). This characteristic of the enzyme
may explain why the mutation described in our study leads
to loss of presentation. The full specificity of ERAPI has
yet to be defined, however, and our data additionally show
failure of the QP-ISW9 peptide to be cleaved to ISW9.
Our studies do not exclude the possibility that other steps
involved in antigen processing may have been affected by
the A146P mutation. Potential sites for processing escape
mutations include the cleavage of proteins by proteasomes
(56) and the translocation of the peptide into the ER by
TAP (21, 22, 54, 57). It has been shown that a proline at
position 2 or 3 of a peptide decreases its translocation rate
via TAP (58, 59). Yellen-Shaw et al. (30), examining an
experimentally induced A→P substitution flanking the
NH2 terminus of an epitope, could not explain the loss
of epitope presentation by interference with proteasome
cleavage or poor transport by TAP. Failure of ERAPI to
trim the NH2-terminal flanking residues may therefore
contribute substantially to the processing escape mechanism
in the example described here.
The extent to which processing mutation is an immune
escape mechanism used by pathogens is unknown. There
are obstacles to identifying processing mutations, the first of
which is defining the CTL epitopes themselves. Although
no virus has received more intensive research attention
than HIV, only a small minority of all the HIV-specific
CTL epitopes that are targeted have been defined to date
(60, 61). A second difficulty in detecting potential process-
ing mutants is that variation occurring outside defined CTL
epitopes might be the consequence of selection pressures
other than those driving processing escape mutations. This
would include compensatory mutations enabling the virus
to achieve improved fitness after a deleterious mutation
arising elsewhere (13, 37), and mutations occurring within
other epitopes than the one under study. However, there
are indications that processing escape is a mechanism more
widely used than is currently apparent. First, perusal of the
defined HIV-specific CTL epitopes shows that the occur-
rence of proline at the position immediately preceding the
NH2 terminus of CTL epitopes is rare: only 6 out of 187
defined HIV-specific epitopes have a proline residue at po-
sition  1. In at least one case, the Nef epitope QVPLRP-
MTYK, turns out to be dependent not upon ERAPI for
processing but upon TPPII (24). Second, Moore et al. (62)
described associations between viral sequence mutations
and certain HLA alleles, a substantial proportion of which
are not within defined epitopes and a number of which
were present in the immediate flanking region of defined
epitopes. Finally, a second processing mutation adjacent to
the C terminus of the HLA-A3–restricted p17 Gag epitope
KIRLRPGGK has recently been identified (63). This time
it is not a mutation impairing ERAPI activity, but po-
tentially a proteasomal or other endoproteolytic enzyme.
Thus, we believe that processing escape mutations such as
the one we have described in this paper might be substan-
tially more frequent than hitherto recognized.
In conclusion, this is the first report not only to define
intrahost viral escape via mutation in the flanking region of
a CTL epitope in a natural human infection, but also to
identify a potential mechanism of this processing failure.
Failure of ERAPI to process the mutant peptide resulted in
an inability of the optimal epitope to be generated. It will
be important to evaluate whether this mutation also affects
other steps of the processing pathway and to define further
the role of viral escape as a consequence of antigen process-
ing failure. The A146P mutation itself does not influence
the replicative capacity of the virus and the accumulation
over time of this processing escape mutation in the popula-
tion of viruses circulating through the epidemic may there-
fore ultimately lead to the extinction of this epitope as a
CTL target, even though the epitope itself may remain in-
variant. These data extend the knowledge about viral es-
cape mechanisms and have implications for vaccine design,
both in terms of vaccine construction and also to take into
account HIV-1 evolution as the epidemic proceeds.
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